Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 12 , Pages 1527-1532 , December 2006

Pharmacological Management of a Youth With ADHD and a Seizure Disorder

,Accepted 26 July 2006.

REFERENCES 

  1. Aldenkamp A , Arends J . The relative influence of epileptic EEG discharges, short nonconvulsive seizures and type of epilepsy on cognitive function . Epilepsia . 2004;45:54–63
  2. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2006), Canadian ADHD Practice Guidelines, First Edition. Available at: http://www.caddra.ca/english/phys_guide.html. Accessed May 25, 2006
  3. Feldman H , Crumrine P , Handen BL , Alvin R , Teodori J . Methylphenidate in children with seizures and attention-deficit disorder . Am J Dis Child . 1989;143:1081–1086
  4. Gonzalez-Heydrich J, Hsin O, Hickory M et al. (2004), Comparisons of response to stimulant preparations in pediatric epilepsy. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19-24
  5. Gonzalez-Heydrich J, Whitney J, Hsin O et al. (2006), Tolerability of OROS MPH for Treatment of ADHD Plus Epilepsy. Presented at the Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June 12-16
  6. Gross-Tsur V , Manor O , van der Meere J , Joseph A , Shalev RS . Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? . J Pediatr . 1997;130:670–674
  7. Gucuyener K , Erdemoglu AK , Senol S , Serdaroglu A , Soysal S , Kockar AI . Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities . J Child Neurol . 2003;18:109–112
  8. Hernández A, Barragán P (2005), Efficacy of atomoxetine treatment in children with ADHD and epilepsy. Presented at the Annual Meeting of the International League Against Epilepsy, Paris, August 18-September 1
  9. Ounsted C . The hyperkinetic syndrome in epileptic children . Lancet . 1955;2:303–311
  10. Sánchez-Carpintero R , Neville BG . Attentional ability in children with epilepsy . Epilepsia . 2003;44:1340–1349
  11. Schubert R . Attention deficit disorder and epilepsy . Pediatr Neurol . 2005;32:1–10
  12. Schaller JL , Behar D . Carbamazepine and methylphenidate in ADHD . J Am Acad Child Adolesc Psychiatry . 1999;38:112–113
  13. Semrud-Clikeman M , Wical B . Components of attention in children with complex partial seizures with and without ADHD . Epilepsia . 1999;40:211–215
  14. Tan M , Appleton R . Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy . Arch Dis Child . 2005;90:57–59
  15. Wernicke JF, Chilcott K, McAfee A et al. (2005), Seizure risk in patients with ADHD treated with atomoxetine. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, October 18-23

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. While it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil has received grant support from and is a consultant to and/or member of the speakers' bureaus of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Dunn has received grant support from and is a consultant to and/or member of the speakers' bureau of Eli Lilly, AstraZeneca, Otsuka, and McNeil. Dr. Gonzalez-Heydrich has received grant support from and is a consultant to and/or member of the speakers' bureaus of Pfizer, Abbott Laboratories, Cyberonics, Janssen Pharmaceutical Research Foundation, McNeil Consumer and Specialty Pharmaceuticals, Novartis, GlaxoSmithKline, and Eli Lilly. Dr. Weiss is a consultant to and serves on the advisory boards of Eli Lilly, Janssen, Shire, Purdue, Circa Dia, Novartis, and Cephalon; is a speaker for Eli Lilly, Janssen, Shire, Novartis, and Cephalon; and has received research support from Eli Lilly, Janssen, Shire, Purdue, and Circa Dia. Dr. Plioplys is a member of the speakers' bureau of Novartis. Dr. Jan has received grant support from and is a consultant to and/or member of the speakers' bureau of Circa Dia and Telethon. The other authors have no financial relationships to disclose.

PII: S0890-8567(09)61811-6

doi: 10.1097/01.chi.0000240836.71361.39

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 12 , Pages 1527-1532 , December 2006

Article Tools